CordenPharma International and GE Healthcare’s Dharmacon business have entered a collaboration to create an end-to-end solution for oligonucleotide-based drug discovery.
The collaboration will address the speed and capacity challenges researchers face when transitioning from research and preclinical stages to drug development and clinical trials. This changeover requires customers to move from a technology vendor to a contract manufacturing organization; compounding this step are capacity challenges in the biotech contract manufacturing marketplace. The collaboration between CordenPharma and GE Healthcare Dharmacon will provide biotech and pharmaceutical customers with a new option to address these challenges.
“Through this agreement, we are bringing GE Healthcare’s Dharmacon product line, which offers leading technical expertise in research-scale design and manufacturing, together with CordenPharma’s deep experience in contract manufacturing,” said Olivier Loeillot, General Manager of GE Healthcare’s Genomics & Cellular Research business. “We can help customers move faster by working together and provide an offering that takes them from bench to batch with one partner.”